The episode argues that biotechnology ventures often collapse financially while their underlying scientific innovations remain viable, leading to the avoidable loss of valuable intellectual property and specialized human capital. To combat this, the author proposes a policy shift toward IP-centric restructuring and the formation of new companies well before formal insolvency occurs. Current barriers to this transition include legal entanglements, high financial friction, and the social stigma of corporate failure, which often delay action until assets have significantly degraded. Experts suggest utilizing standardized templates, regulatory safe harbors, and feasibility funding to streamline the preservation of technology and teams. Ultimately, restructuring is framed as a rational phase of the innovation lifecycle that protects societal investment in science rather than just the survival of a specific corporate entity.

#Bioprocess #ScaleUp and #TechTransfer,

#Industrial #Microbiology,

#MetabolicEngineering and #SystemsBiology,

#Bioprocessing,

#MicrobialFermentation,

#Bio-manufacturing,

#Industrial #Biotechnology,

#Fermentation Engineering,

#ProcessDevelopment,

#Microbiology, #Biochemistry

#Biochemical Engineering,

#Applied #MicrobialPhysiology,

#Microbial #ProcessEngineering,

#Upstream #BioprocessDevelopment,

#Downstream Processing and #Purification,

#CellCulture and #MicrobialSystems Engineering,

#Bioreaction #Enzymes

#Biocatalyst

#scientific

#Scientist

#Research